By the Top Tier Newswire AI Desk · August 27, 2026 at 12:16 AM ET · reviewed against 1 wire stories
ERASCA INC (ERAS) is up +7.83% in the latest session. Our newswire has captured 1 story on ERAS across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ERAS stock is up 7.83% to $19.15 in today’s session, driven by a combination of recent analyst upgrades and regulatory developments. The stock has risen on the back of Fast Track Designation from the FDA for its candidate ERAS-0015 in treating metastatic pancreatic adenocarcinoma, as well as updated price targets from multiple analysts. These developments have contributed to a positive shift in investor sentiment over the past week.
What Happened
Erasca Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to ERAS-0015 for the treatment of metastatic pancreatic adenocarcinoma. This regulatory milestone is intended to expedite the development and review of therapies for serious conditions with unmet medical needs. The news comes as a key development for the company, which reported a second-quarter loss of $0.14 per share, missing the $0.11 estimate. Despite the earnings miss, the stock has benefited from a series of analyst actions. B of A Securities, Guggenheim, and HC Wainwright & Co. have all raised their price targets, with B of A setting a new $20 target, Guggenheim at $21, and HC Wainwright at $22. All three firms maintain Buy or Neutral ratings on the stock.
What The Data Shows
The stock has traded in a 52-week range of $1.33 to $24.28 and has a market capitalization of $6.2 billion. Over the last 8 sessions, the stock has risen 3.7% from $18.28 to $18.96. The 30-day average sentiment score has improved from 50/100 to 64/100 in the last 7 days. The stock also printed 9 fresh 52-week highs and 5 fresh 52-week lows on August 27, 2026, indicating a volatile and active trading environment.
What To Watch
Investors will be watching for the company’s next earnings report to assess progress and financial health. In the absence of a scheduled earnings date, broader analyst coverage and regulatory developments will remain key indicators for the stock’s near-term direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ERAS · Aug 27 session (5-min) · +1.83% vs prior close · updated 8:48 PM ETAI sentiment, last 36h · averaged over 1 story · 50/100 neutral
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
18d agoGlobeNewswireNEUTRAL 50General
Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); New Era Energy & Digital, Inc. (NASDAQ: NUAI) (formerly known as New Era Helium (NASDAQ: NEHC)); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
Erasca, Inc. (NASDAQ: ERAS); Insulet Corp. (NASDAQ: PODD); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions Int
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →